

Fluoroquinolone-Resistant *Helicobacter pylori* strains Isolated from One Egyptian University Hospital: Molecular Aspects

MAYSAA EL SAYED ZAKI¹, WALAA OTHMAN², MAHMOUD ABDELWAHAB ALI², AHMED SHEHTA²

¹Clinical Pathology Department, Mansoura Faculty of Medicine, Egypt;

²Gastroenterology Surgical Center, Mansoura Faculty of Medicine, Egypt

Received 11 January 2016

Accepted 27 March 2016

Introduction

Helicobacter pylori (*H. pylori*) are fastidious Gram negative rods responsible for a wide variety of gastrointestinal disorders ranging from simple dyspepsia up to gastric adenocarcinoma [1-5]. Treatment of gastrointestinal disorders caused by *H. pylori* is a combination of antibiotics usually amoxicillin and metronidazole or clarithromycin besides an acid suppressor.

The combination of two antibiotics is used to increase the eradication rates of *H. pylori* and decrease the development of antibiotic resistance [6,7]. The resistance pattern of organisms parallels the patterns of antibiotics consumption in the community. So, the prediction of antibiotics resistance rate among different geographical localities is the main goal of microbiological laboratories to eradicate resistant *H. pylori* strains [8]. There is increasing rates of resistance of *H. pylori* toward clarithromycin reported in various studies [9,10]. This leads to introduction of fluoroquinolones as an alternative substitute to antibiotics used in treatment of *H. pylori* [6,7]. In several studies, the use of fluoroquinolones has provided a successful alternative therapy in persistent *H. pylori* infections [11,12]. The mode of action of fluoroquinolones as bactericidal antibiotic is carried out by the inactivation of deoxyribonucleic acid (DNA) gyrase and topoisomerase enzymes that control

Correspondence to: Dr. Maysaa El Sayed Zaki

Email: may_s65@hotmail.com

ABSTRACT

Objective: The aim of the present study was to determine in vitro susceptibility of isolated *Helicobacter pylori* strains to fluoroquinolones by disc diffusion method and by genotypic method using polymerase chain reaction and sequencing for determination of *gyrA* gene mutations at positions 87 and 91 of the *H. pylori*.

Methods: The study included eighty two adult patients complaining of upper gastrointestinal disorders. Biopsy samples were obtained from patients with endoscope and subjected to microbiological culture for *H. pylori*. Antibiotics susceptibility was determined for the isolates to clarithromycin, amoxicillin, metronidazole, ciprofloxacin and levofloxacin. Strains of *H. pylori* resistant to ciprofloxacin were subjected to study by polymerase chain reaction and sequencing for determination of *gyrA* gene mutations at positions 87 and 91 of the *H. pylori*.

Results: There were high antibiotic resistance tendencies toward clarithromycin (71%) and amoxicillin (47.8%) among isolated *H. pylori* strains, while resistance patterns were less towards ciprofloxacin (28.9%), levofloxacin (23.2%) and metronidazole (21.7%). *GyrA* gene mutations were detected in 19 (95%) *H. pylori* isolates resistant to ciprofloxacin with the most common type mutations in codon A at amino acid position Asp-91 in 12 (63.2%) isolates followed by point mutations at amino acid Asn-87 in 7 (36.8%) isolates. Only one resistant *H. pylori* strain toward ciprofloxacin had no detected mutations in *gyrA* gene.

Conclusions: The present study highlights the high prevalence of *H. pylori* resistant strains to amoxicillin and clarithromycin which thought to be the first line of antibiotics therapy. The study draws attention that fluoroquinolone resistance is less than that for first line therapy which may be a better substitute for first line antibiotics. The mechanism of fluoroquinolone resistance is mainly associated with *gyrA* gene mutations most commonly in the *gyrA* protein at position 91.

KEY WORDS: *Helicobacter pylori*
Fluoroquinolone
gyrA,
PCR

DNA in cells and interfere with bacterial DNA replication. The structures of these enzymes are formed of two A and two B subunits, encoded by the *gyrA* and *gyrB* genes (8). However, even with the use of fluoroquinolone as a new therapy for *H. pylori*, therapeutic failure rates were reported due to the development of bacterial resistance [13-15]. The resistance to fluoroquinolone in *H. pylori* has been attributed to mutations in the quinolone resistance determining regions of the *gyrA* and the *gyrB* genes. The most significant mutations conferring quinolone resistance lie at positions 87 and 91 of the *H. pylori gyrA* gene. These findings of *H. pylori* resistance patterns differ according to the geographical region thus making laboratory detection of antibiotics resistance pattern a mandatory tool for *H. pylori* eradication [16]. Laboratory determination of *H. pylori* antimicrobial susceptibility can be performed either by phenotypic or by genotypic methods. Phenotypic methods include disc diffusion method, agar dilution method and E-test [17-20]. The main disadvantage of phenotypic methods is the fact that *H. pylori* are a slow growing organism. On the other hand molecular method is a rapid method. The aim of the present study was to determine in vitro susceptibility of isolated *H. pylori* strains to fluoroquinolones by disc diffusion method and by genotypic method using polymerase chain reaction and sequencing for determination of *gyrA* gene mutations at positions 87 and 91 of the *H. pylori*.

Materials and Methods

The study included eighty-two adult patients complaining of gastrointestinal symptoms undergoing upper gastrointestinal endoscopes from January 2015 until August 2015. The patients were referred from Gastroenterology Center, Mansoura University, Egypt. The study was approved by the ethical committee of Mansoura Faculty of medicine. Approval consent was obtained from each participating subject. Biopsies were obtained from the greater curvature of stomach about 2 cm from pylorus, and transported to the laboratory on phosphate buffered saline in sterile container. In the lab each biopsy was cultured after homogenization over Columbia blood agar supplied with 5% sheep blood (Oxoid Columbia agar base) and the antibiotic supplements. Plates were incubated at 37°C up to 2-3 days in a microaerophilic atmosphere by use of gas packs (Campy

Pak; Becton Dickinson) in an anaerobic jar. Identification of *H. pylori* was made by Gram staining of the colonies and testing for the presence of urease, oxidase and catalase [21].

Antibiotics susceptibility of *H. pylori*

Antibiotics susceptibility of isolated *H. pylori* strains was performed using the disc diffusion method for amoxicillin, levofloxacin, clarithromycin, metronidazole and ciprofloxacin with preparing inoculums density equivalent of 3.0 McFarland units over Muller-Hinton agar under microaerophilic condition for 72 hours. Pure colonies of *H. pylori* were kept in Schaedler broth at -70°C for further molecular studies for detection of *gyrA* gene mutations for resistance to fluoroquinolones.

PCR for *gyrA* gene

Extraction of DNA

Broth culture of *H. pylori* found resistant to ciprofloxacin was taken for extraction of DNA. Extraction was done by the use of QIAamp DNA Mini Kit (Qiagen, USA) according to the manufacturer's instructions.

Amplification of the extracted DNA

Amplification of the eluted DNA was performed in a 50 µl reaction volume for the detected gene. *Gyr* APF (5'-AGCTTATTCCATGAGCGTGA-3') and *gyr* APR (5'-TCAGGCCCTTTGACAAATTC-3') were designed to amplify a 582 bp amplicon. The PCR mix consisted of 25 µl of master mix containing HotStar Taq DNA Polymerase, PCR buffer (with 3 mM MgCl₂), and 400 µM each dNTP, 10 µl of the eluted DNA, 1 µl of each primer (50 pM) of the gene to be detected and 13 µl distilled water. Amplification of DNA was performed in a thermal cycler (thermo PxE 0.21, England) and included initial denaturation for 5 min, followed by 35 cycles of 94°C for 30 s, 53°C for 30 s and 72°C for 30 s, with a final extension step of 72°C for 10 min. The reaction products were visualized by running 5 µl of the reaction mixture on 1.5% agarose gel [8].

Sequencing

Amplified PCR products were purified by the use of QIA quick PCR purification kit (Qiagen). Later on the purified PCR extracts were subjected to sequence study of *gyrA* gene with the ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction Kit v3.1 (Applied Biosystems,

Germany) using the PCR primers as sequencing primers and the obtained results were analyzed with sequencing analysis software (Genecodes, USA).

Statistical analysis

Data entry and analysis were performed using SPSS version 16. The data were expressed as mean \pm SD and percentages.

Results

The study included 82 adult patients complaining of upper gastrointestinal disorders underwent gastroduodenal endoscope examinations. They were 42 (51.2%) male and 40 (48.8%) female with mean age 43 ± 8.5 years. Previous antibiotics therapy for *H. pylori* was reported from 25 (30.5%) patients. Positive culture for *H. pylori* was detected in 69 patients (84.1%), table 1. There were high antibiotic resistance tendencies towards clarithromycin (71%) and amoxicillin (47.8%) among isolated *H. pylori* strains, while resistance patterns were less towards ciprofloxacin (28.9%), levofloxacin (23.2%) and metronidazole (21.7%), table 2. GyrA gene mutations were detected in 19 (95%) *H. pylori* isolates resistant to ciprofloxacin with the most common type of mutations in codon A at amino acid position Asp-91 in 12 (63.2%) resistant isolates followed by point mutations at amino acid Asn- 87 in 7 (36.8%) resistant isolates. Only one resistant *H. pylori* strain toward ciprofloxacin had no detected mutations in gyrA gene (table 3).

Discussion

H. pylori is a common pathogen causing upper gastrointestinal tract disorders especially in less developed countries due to low socioeconomic standards and bad sanitary conditions. With the increasing frequency of resistance among *H. pylori* strains, there is rising concern about the potential decline in the eradication rate of this infection and therefore an urgent need to introduce other treatment options. In the present study culture of *H. pylori* from symptomatic adults yielded high positive rate (84.1%).

Table 1. Demographic data and positive findings of the studied cases.

Descriptive data of the studied cases	
Sex	
Male No. (%)	42 (51.2%)
Female No. (%)	40 (48.8%)
Age (mean \pm SD) years	43 \pm 8.5
Previous therapy No. (%)	25 (30.5%)
Positive culture for <i>H. pylori</i> No. (%)	69 (84.1%)

Table 2. Antibiotics resistance pattern among *H. pylori* isolates (n=69).

Antibiotics	N0. (%)
Clarithromycin	49 (71%)
Amoxicillin	33 (47.8%)
Metronidazole	15 (21.7%)
Ciprofloxacin	20 (28.9%)
Levofloxacin	16 (23.2%)

Table 3. Frequency of GyrA gene mutations in resistant *H. pylori* isolates to ciprofloxacin (n=20).

GyrA mutations	N0. (%)
Mutations	19 (95%)
Point mutations Asp-91	12 (63.2%)
Point mutations Asn-87	7 (36.8%)
No mutations	1 (5.0%)
Total	20 (100%)

These results are in agreement with previous results that stated that infections rates for adults by *H. pylori* ranges from 47.2 up to 90% [5-7,22]. Endoscopy is required for diagnosis of gastrointestinal symptoms especially in patients above the age of 45 years with new upper gastrointestinal complaints [23,24]. It is also a valuable tool to obtain biopsy for microbiological culture and accurate determination of antibiotics susceptibility of *H. pylori*. There have been many reports about therapeutic failure of *H. pylori* due to development of antibiotics resistance. The results from different geographical regions indicate that the effectiveness of therapeutic regimen differs according to antibiotic resistant rates for *H. pylori* which depends upon antibiotics consumption policy [25].

In the present study there were high antibiotic resistance tendencies toward clarithromycin (71%) and amoxicillin (47.8%) among isolated *H. pylori* strains, while resistance patterns were less towards ciprofloxacin (28.9%), levofloxacin (23.2%) and metronidazole (21.7%). Fathi et al., (2013) [26] reported high resistance rates among *H. pylori* isolated from one Egyptian center that constituted 87.5% for amoxicillin, 100% for each of clarithromycin and metronidazole and 12.5% for ciprofloxacin. High rates of resistance towards amoxicillin of isolated *H. pylori* were reported by previous studies that ranged from 19.4% up to 100% (27-30). Also, high rates of *H. pylori* resistance to clarithromycin that ranged from 32% to 45.2% were reported by previous studies [31,32].

Though much lower rates of resistance of *H. pylori* to clarithromycin were reported in other studies that ranged from 14.3% to 17.9% [33,34]. The high rate of clarithromycin and amoxicillin resistance detected in this study is likely to be attributed to an overuse of these antibiotics for the treatment of upper respiratory tract infections and gastrointestinal tract disorders.

In general, the first line therapy for *H. pylori* includes acid suppressors with the use of antibiotics namely clarithromycin and amoxicillin [34]. Metronidazole can be used instead of amoxicillin in certain conditions like in patients with a penicillin allergy due to the increase failure rates of this therapy [35,36]. The use of quinolone or rifabutin is preferred especially after antimicrobial susceptibility testing and in geographical regions where high rates of resistance is anticipative [35,37,38].

The common mutations responsible for quinolone resistance are located at positions 87 and 91 of the *H. pylori* *gyrA* gene, which encodes the A subunit of the DNA gyrase enzyme [39,40].

Resistance to fluoroquinolones is generally very low (<10%) worldwide. In our study we found a low resistance rate for ciprofloxacin (28.9%) and levofloxacin (23.2%). Lower rates of resistance to quinolones were reported by previous study in Egypt and represented 12.5% by using the same susceptibility testing as in the current study (Fathi et al., 2013) and by other authors [34,41]. The rate reported in this study is lower than that detected by other studies that was high up to 34.5% [31,32].

Our results draw attention towards better treatment of *H. pylori* to guard against chronicity and developments of its

complications. It appears that we have to change the therapeutic policies for *H. pylori* by the use of ciprofloxacin and metronidazole. If the culture and antimicrobial susceptibility is available, it will be an appropriate choice to wait for the antimicrobial results.

To study the mechanism of fluoroquinolone resistance in isolated *H. pylori* strains we performed PCR and subsequent sequence study of *gyrA* region claimed to be responsible for resistance. The mechanism of fluoroquinolone resistance in *H. pylori* has been found to be associated with mutations in the quinolone resistance-determining regions (QRDRs) of the *gyrA* gene.

Our findings had shown that fluoroquinolone resistance in *H. pylori* is due mainly (95%) to mutations in the QRDR of *gyrA* with the most common type mutations in codon A at amino acid position 91 was found in 12 (63.2%) resistant isolates followed by point mutations at amino acid 87 in 7 (36.8%) resistant isolates. Only one resistant *H. pylori* strain toward ciprofloxacin had no detected mutations in *gyrA* gene. It has been reported that the prevalence of mutations rates vary from one country to another [42]. In one study in Hong Kong the most frequent mutation site in the *gyrA* protein was position 91 [43]. We could not find any studies about the frequency of *gyrA* mutations in Egypt.

The present study highlights the high prevalence of *H. pylori* resistant strains to amoxicillin and clarithromycin which are thought to be the first line of antibiotics therapy. The study draws attention that fluoroquinolone resistance is less than that for first line therapy which may be a better substitute for first line antibiotics. The mechanism of fluoroquinolone resistance is mainly associated with *gyrA* mutations most commonly point in the *gyrA* protein at position 91.

Conflict of Interest

We declare that we have no conflict of interest.

References

- 1 Zhou L, Sung JJ, Lin S, Jin Z, Ding S, Huang X, et al. Five-year follow-up study on the pathological changes of gastric mucosa after *H. pylori* eradication. *Chin Med J (Engl)*. 2003;116:11-4.
- 2 Miwa H, Sakaki N, Sugano K, Sekine H, Higuchi K, Uemura N, et al. Recurrent peptic ulcers in patients following successful *Helicobacter pylori* eradication: a multicenter study of 4940 patients. *Helicobacter*. 2004;9:9-16.

- 3 Nervi G, Liatopoulou S, Cavallaro LG, Gnocchi A, Dal-Bo N, Rugge M, et al. Does *Helicobacter pylori* infection eradication modify peptic ulcer prevalence? A 10 years' endoscopical survey. *World J Gastroenterol.* 2006;12:2398-401.
- 4 Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive *Helicobacter pylori* eradication therapy: experience from a large prospective series. *Gut.* 2004;53:34-7.
- 5 Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. *Helicobacter pylori* eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. *JAMA.* 2004;291:187-94.
- 6 Malfertheiner P, Megraud F, O'Morain C, Hungin A, Jones R, Axon A, et al. Current concepts in the management of *Helicobacter pylori* infection: the Maastricht 2–2000 Consensus Report. *Aliment Pharmacol Ther* 2002; 16:167-80.
- 7 Hu FL, Hu PJ, Liu WZ, De Wang J, Lv NH, Xiao SD, et al. Third Chinese national consensus report on the management of *Helicobacter pylori* infection. *J Dig Dis.* 2008;9:178-84.
- 8 Wang LH, Cheng H, Hu FL, Li J. Distribution of *gyrA* mutations in fluoroquinolone-resistant *Helicobacter pylori* strains. *World J Gastroenterol.* 2010;16(18):2272-7.
- 9 Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, et al. Low eradication rate of *Helicobacter pylori* with triple 7–14 days and quadruple therapy in Turkey. *World J Gastroenterol.* 2004;10:668-71.
- 10 Chinese *Helicobacter pylori* Research Group, Chinese Society of Gastroenterology. Prevalence of *Helicobacter pylori* resistance to antibiotics and its influence on the treatment outcome in China: a multicenter clinical study. *Weichang Bingxue.* 2007; 12:525-30.
- 11 Eisig JN, Silva FM, Barbuti RC, Rodriguez TN, Malfertheiner P, Moraes Filho JP, et al. Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed *Helicobacter pylori* eradication. *BMC Gastroenterol.* 2009;9:38.
- 12 Di Caro S, Ojetti V, Zocco MA, Cremonini F, Bartolozzi F, Candelli M, et al. Mono, dual and triple moxifloxacin-based therapies for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther.* 2002;16:527-32.
- 13 Yoon H, Kim N, Lee BH, Hwang TJ, Lee DH, Park YS, et al. Moxifloxacin-containing triple therapy as second-line treatment for *Helicobacter pylori* infection: effect of treatment duration and antibiotic resistance on the eradication rate. *Helicobacter.* 2009;14:77-85.
- 14 Perri F, Festa V, Merla A, Barberani F, Pilotto A, Andriulli A. Randomized study of different 'second-line' therapies for *Helicobacter pylori* infection after failure of the standard 'Maastricht triple therapy' *Aliment Pharmacol Ther.* 2003;18:815-20.
- 15 Yee YK, Cheung TK, Chu KM, Chan CK, Fung J, Chan P, et al. Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant *Helicobacter pylori* infection. *Aliment Pharmacol Ther.* 2007;26:1063-7.
- 16 Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. Influence of efflux pump inhibitors on the multidrug resistance of *Helicobacter pylori*. *World J Gastroenterol.* 2010;16(10):1279-84.
- 17 Glupczynski Y, Labbe M, Hansen W, Crokaert F, Yourassowsky E. Evaluation of the E test for quantitative antimicrobial susceptibility testing of *Helicobacter pylori*. *J Clin Microbiol.* 1991;29(9):2072-5.
- 18 Hirschl AM, Hirschl MM, Rotter ML. Comparison of three methods for the determination of the sensitivity of *Helicobacter pylori* to metronidazole. *J Antimicrob Chemother.* 1993;32:45-9.
- 19 De Cross AJ, Marshall BJ, McCallum RW, Hoffman SR, Barrett LJ, Guerrant RL. Metronidazole susceptibility testing for *Helicobacter pylori*: comparison of disk, broth, and agar dilution methods and their clinical relevance. *J Clin Microbiol* 1993;31:1971-4.
- 20 Chaves S, Gadanho M, Tenreiro R, Cabrita J. Assessment of metronidazole susceptibility in *Helicobacter pylori*: statistical validation and error rate analysis of breakpoints determined by the disk diffusion test. *J Clin Microbiol.* 1999;37:1628-31.
- 21 Logan RP, Walker MM. ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of *Helicobacter pylori* infection. *BMJ.* 2001;323 (7318):920-2.
- 22 Ozcakir O, Yonem O, Demir H, Altinbas A, Altinok G, Orhan D, et al. Comparison of three methods: culture, real-time PCR and fluorescent in situ hybridisation in detecting of *Helicobacter pylori*. *Molecular detection of bacterial species ECCMID.* 2008:1983.
- 23 Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of *Helicobacter pylori* infection--the Maastricht IV/ Florence Consensus Report. *Gut.* 2012; 61(5):646-64.
- 24 Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut.* 2007; 56(6):772-81.
- 25 Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. Influence of efflux pump inhibitors on the multidrug resistance of *Helicobacter pylori*. *World J Gastroenterol.* 2010;16(10):1279-84.
- 26 Fathi M S, EL-Folly RF, Hassan RA, El-Arab ME. Genotypic and phenotypic patterns of antimicrobial susceptibility of *Helicobacter pylori* strains among Egyptian patients *The Egypt J of Med Human Gen.* 2013 14, 235-46.
- 27 Aboderin OA, Abdu AR, Odetoyin B, Okeke IN, Lawal OO, Ndububa DA, et al. Antibiotic resistance of *Helicobacter pylori* from patients in Ile-Ife, Southwest Nigeria. *Afr Health Sci* 2007;7(3):143-7.

- 28 Okimoto T, Murakami K. Acquisition of the drug resistance and *Helicobacter pylori* gene mutation. *Nippon Rinsho*. 2009;67:2372-7.
- 29 Godoy AP, Ribeiro ML, Benvenuto YH, Vitiello L, Miranda Mde C, Mendonça S, et al. Analysis of antimicrobial susceptibility and virulence factors in *Helicobacter pylori* clinical isolates. *BMC Gastroenterol*. 2003;3:20.
- 30 Kumala W, Rani A. Patterns of *Helicobacter pylori* isolate resistance to fluoroquinolones, amoxicillin, clarithromycin and metronidazoles. *Southeast Asian J Trop Med Public Health*. 2006;37:970-4.
- 31 Abadi A, Taghvaei T, Mobarez A, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in *Helicobacter pylori* strains isolated from the northern population of Iran. *J Microbiol*. 2011;49(6):987-93.
- 32 Ilie M, Popa M, Chifiriuc M, Baltac A, Constantinescu G, Tănăsescu C. *Helicobacter pylori* cultivation from gastric biopsies and susceptibility to antibiotics used in empirical therapy. *Roum Arch Microbiol Immunol*. 2011;70(2):60-4.
- 33 Milani M, Ghotaslou R, Akhi M, Nahaei M, Hasani A, Somi M, et al. The status of antimicrobial resistance of *Helicobacter pylori* in Eastern Azerbaijan, Iran: comparative study according to demographics. *J Infect Chemother*. 2012(5):12.
- 34 Boyanova L, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, et al. Numerous risk factors for *Helicobacter pylori* antibiotic resistance revealed by extended anamnesis: a Bulgarian study. *J Med Microbiol*. 2012;61(Pt 1):85-93.
- 35 Chang SS, Hu HY. *Helicobacter pylori*: Effect of coexisting diseases and update on treatment regimens. *World J Gastrointest Pharmacol Ther*. 2015 Nov 6;6(4):127-36.
- 36 Iwańczak F, Iwańczak B. Treatment of *Helicobacter pylori* infection in the aspect of increasing antibiotic resistance. *Adv Clin Exp Med*. 2012; 21:671-80.
- 37 Toracchio S, Capodicasa S, Soraja DB, Cellini L, Marzio L. Rifabutin based triple therapy for eradication of *H. pylori* primary and secondary resistant to tinidazole and clarithromycin. *Dig Liver Dis*. 2005;37:33-8.
- 38 Gisbert JP, Bermejo F, Castro-Fernández M, Pérez-Aisa A, Fernández-Bermejo M, Tomas A, et al. Second-line rescue therapy with levofloxacin after *H. pylori* treatment failure: a Spanish multicenter study of 300 patients. *Am J Gastroenterol*. 2008;103:71-6.
- 39 Rimbara E, Noguchi N, Kawai T, Sasatsu M. Fluoroquinolone resistance in *Helicobacter pylori*: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB. *Helicobacter*. 2012 ;17(1):36-42.
- 40 Glocker E, Stueger HP, Kist M. Quinolone resistance in *Helicobacter pylori* isolates in Germany. *Antimicrob Agents Chemother*. 2007;51: 346-9.
- 41 Chung J, Lee G, Jeong J, Lee SM, Jung JH, Choi KD, et al. Resistance of *Helicobacter pylori* strains to antibiotics in Korea with a focus on fluoroquinolone resistance. *J Gastroenterol Hepatol*. 2012;27(3):493-7.
- 42 Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in *Helicobacter pylori* strains from Korean patients. *J Antimicrob Chemother* 2005;56:965-7.
- 43 Lee CC, Lee VW, Chan FK, Ling TK. Levofloxacin-resistant *Helicobacter pylori* in Hong Kong. *Chemotherapy*. 2008;54:50-3.